Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, and Mabgeek, a clinical-stage…
Blog
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel…
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an…
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before…
Strava and Apple Fitness+ collaborate to motivate and reach more active people in the new year
Strava, the app for active people, and Apple Fitness+, the award-winning fitness and wellness service designed…
Foundry Outpatient Steamboat Opens to Provide High-Quality Behavioral Healthcare to Yampa Valley
Foundry Outpatient Steamboat opens to provide high-quality behavioral healthcare to Steamboat Springs and Yampa Valley residents. Led and staffed…
CBTN Partners with Day One to Drive New Therapies for Pediatric Brain Tumors
The Children’s Brain Tumor Network (CBTN), a consortium of leading pediatric brain tumor research institutions, announces…
Endeavor Health awarded $2m Department of Justice grant for community violence prevention and intervention program
Endeavor Health℠ has been awarded a $2 million, three-year grant from the U.S. Department of Justice Office of Justice Programs to…
iXpressGenes Appoints John Schmitt as CEO, Announces Nationwide TAI Test Launch
iXpressGenes (iXG), a biotechnology company transforming trauma care, is proud to appoint co-founder John Schmitt as Chief Executive…
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies…